https://www.bwxt.com/bwxt-medical/news2353421e-8f6b-45d1-8160-4342bd7508a9https://www.bwxt.com/bwxt-medical/news/2023/12/14/2023-Community-Survey-Report-Now-Available-2023-12-14T10:58:00-05:006ff6ebd2-5073-4371-ac46-7ba751f95fa6https://www.bwxt.com/bwxt-medical/news/2023/11/16/BWXT-Medical-Expands-Collaboration-with-Fusion-Pharmaceuticals-Through-Strengthened-Actinium-Supply-and-Access-to-Generator-Technology(OTTAWA, Ontario – November 16, 2023) – BWXT Medical Ltd. and Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that the companies have entered into an agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials. 2023-11-16T19:55:00-05:0098c50a6f-9194-4dc7-9b2f-38457bfb1e7bhttps://www.bwxt.com/bwxt-medical/news/2023/02/01/BWXT-Medical-and-Laurentis-Complete-Key-Tc-99m-Generator-Program-Milestone(Ottawa, Ontario – February 1, 2023) – Life-saving Molybdenum-99 (Mo-99) isotopes can now be produced at Ontario Power Generation’s (OPG) Darlington Nuclear Generating Station, thanks to the installation and initial commissioning of an innovative isotope system by Laurentis Energy Partners and BWXT Medical Ltd. (NYSE: BWXT). 2023-02-01T06:59:00-05:000d60f0e7-47dd-455b-b4e2-447c65285db0https://www.bwxt.com/bwxt-medical/news/2023/01/05/Fusion-Pharmaceuticals-and-BWXT-Medical-Announce-Actinium-225-Partnership-to-Scale-Supply-for-Developing-Targeted-Alpha-TherapiesFusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a preferred partner agreement for the supply of actinium-225.2023-01-05T17:00:00-05:002fc35678-03be-45e3-ae91-59682e8d9882https://www.bwxt.com/bwxt-medical/news/2022/12/01/BWXT-Medical-Names-Andrea-Greenberg-as-Vice-President-Strategic-ServicesBWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has appointed Andrea Greenberg as vice president, Strategic Services.2022-12-01T08:00:00-05:002a31c842-8f7c-4b64-87a7-a5d5d07bf313https://www.bwxt.com/bwxt-medical/news/2022/10/20/Join-our-Community-WebinarJoin our Community Webinar on November 16, 2022 (7 - 8 p.m.) to learn more about BWXT Medical’s operations in Kanata, Ontario. 2022-10-20T17:02:00-04:00bdf2a517-b41f-4ce9-bc8b-7ea0d7c57471https://www.bwxt.com/bwxt-medical/news/2022/10/12/October-Emergency-Response-Drill---Kanata-Facility2022-10-12T13:11:00-04:0057c56b1c-ccc4-4479-985d-155b9eaa603fhttps://www.bwxt.com/bwxt-medical/news/2022/09/22/Facility-Familiarization-Visit-with-Ottawa-Fire-Services-Friday-September-23-2022On Friday, September 23, 2022, Ottawa Fire Services will be onsite at BWXT Medical’s Kanata facility on 447 March Road for a facility familiarization visit.2022-09-22T10:02:00-04:00fd356118-4e14-4f50-92a0-3e4ebaa4f509https://www.bwxt.com/bwxt-medical/news/2022/09/13/BWXT-Medical-Submits-Tc-99m-Generator-New-Drug-Application-to-FDABWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has submitted a new drug application to the U.S. Food and Drug Administration (FDA) to request approval of its technetium-99m (Tc-99m) generator for diagnostic imaging.2022-09-13T16:08:00-04:0021380f3f-66bf-4116-b21b-aae90c06f3c5https://www.bwxt.com/bwxt-medical/news/2022/06/27/BWXT-Medical-Executes-Commercial-Agreement-with-Bayer-for-Supply-of-Actinium-225-Based-Products(OTTAWA, ON – June 27, 2022) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a commercial agreement with Bayer AG (Bayer) to supply high-purity Actinium-225 (Ac-225). 2022-06-27T06:47:00-04:007b78e53b-b5c1-48e4-aeaa-05961a580a3ehttps://www.bwxt.com/bwxt-medical/news/2022/06/13/BWXT-Medical-and-TRIUMF-Execute-Agreement-for-Manufacture-of-High-Purity-Ac-225-Based-Products-BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes. 2022-06-13T09:36:00-04:00301f845e-e054-42f3-8878-7738487a308ahttps://www.bwxt.com/bwxt-medical/news/2021/09/16/BWXT-Medical-and-Bayer-AG-Enter-into-Agreement-for-the-Development-and-Production-of-Actinium-225-(OTTAWA, Ontario – September 16, 2021) – BWX Technologies, Inc. (NYSE: BWXT) announced today that its BWXT Medical Ltd. subsidiary (BWXT Medical) has entered into an agreement with Bayer AG (Bayer) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products as both companies broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other innovative products.2021-09-16T13:14:00-04:00a851faf3-7c2b-4f96-978f-0d9f5ef94465https://www.bwxt.com/bwxt-medical/news/2021/05/10/BWXT-Medical-Enters-into-a-New-Long-Term-Agreement-with-Boston-Scientific(Ottawa, Ontario – May 10, 2021) – BWXT Medical Ltd. (BWXT Medical) announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company.2021-05-10T07:18:00-04:008ea1e11e-0185-40e9-bb91-16075404b717https://www.bwxt.com/bwxt-medical/news/2021/02/01/BWXT-Names-Nuclear-Medicine-Business-as-BWXT-Medical(LYNCHBURG, Va. – Feb. 1, 2021) – BWX Technologies, Inc. (NYSE: BWXT) today announced that its subsidiary BWXT ITG Canada, Inc., a nuclear medicine company, has been renamed BWXT Medical Ltd. (BWXT Medical), in order to better align with the company’s products, customer base and strategy.2021-02-01T06:47:00-05:00b0095cf7-6f13-42bd-82b0-c89b6f8df8cfhttps://www.bwxt.com/bwxt-medical/news/2020/09/24/OPG-and-BWXT-Make-Significant-Progress-in-Production-of-Life-Saving-Medical-Isotope-at-Darlington-Nuclear-Generating-StationDarlington to become first large-scale nuclear station to produce molybdenum-99.2020-09-24T16:29:00-04:00273206d6-102d-4b6b-b9ac-ad0c143498abhttps://www.bwxt.com/bwxt-medical/news/2020/07/06/BWXT-Appoints-Martyn-Coombs-to-lead-Nuclear-Medicine-Business-as-President-BWXT-ITG-Canada(LYNCHBURG, Va. – July 6, 2020) – BWX Technologies, Inc. (NYSE: BWXT) today announced that Martyn Coombs has been appointed president, BWXT ITG Canada, Inc. (BWXT ITG Canada), effective July 20, 2020. In this role, Coombs will have P&L responsibility for BWXT’s medical isotope business, based in Canada, with facilities in Kanata, Ontario and Vancouver, British Columbia. In addition to leading the existing business, Coombs will also be responsible for guiding the successful launch of BWXT’s technetium-99m generator product line currently in development, and growing the overall business. Coombs will be replacing Tom Burnett, who is retiring. 2020-07-06T16:45:00-04:001406ef53-82b0-4e29-9539-1a82f301542bhttps://www.bwxt.com/bwxt-medical/news/2020/02/25/BWXT-Successfully-Demonstrates-Labeling-of-Cold-Kits-with-its-Mo-99--Tc-99m-TechnologyBWXT announced today that it has successfully labeled technetium-99m (Tc-99m) derived from its proprietary molybdenum-99 (Mo-99) production process and its proprietary Tc-99m generators with nine of the most widely used cold kits in the North American market. 2020-02-25T06:45:00-05:0043729a7e-a7db-46a6-beaf-6ade7714c3fahttps://www.bwxt.com/bwxt-medical/news/2019/10/30/BWXT-to-Produce-Medical-Radioisotope-Germanium-68-to-Address-Rise-in-Demand2019-10-30T06:45:00-04:001cb81b0b-0f93-4cca-b2b4-36e33caa80f4https://www.bwxt.com/bwxt-medical/news/2019/09/25/BWXT-Announces-Availability-of-FDA-Approved-Indium-In-111-Oxyquinoline-Solution(LYNCHBURG, Va. – September 26, 2019) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT ITG Canada, Inc., having received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application for its generic version of Indium In-111 Oxyquinoline Solution, is now making the product available for sale in the United States.2019-09-25T11:09:00-04:00a510fbe3-0776-45ef-92a4-fa2a1a11fa64https://www.bwxt.com/bwxt-medical/news/2018/07/12/BWXT-Signs-Medical-Isotope-Development-Agreement-with-Bruce-Power(LYNCHBURG, Va. – July 12, 2018) – BWX Technologies, Inc. (NYSE:BWXT) announced today that a subsidiary has signed an agreement with Bruce Power that will enable the two companies to collaborate on the development and supply of medical isotopes.2018-07-12T06:26:00-04:001834b60b-436c-4deb-bc38-8528edcb99b4https://www.bwxt.com/bwxt-medical/news/2018/06/20/BWXT-Selects-Ontario-Power-Generation-to-Provide-Irradiation-Services-for-New-Medical-Isotope-Manufacturing-TechnologyBWX Technologies, Inc. is expanding its longstanding relationship with Ontario Power Generation (OPG), whose wholly owned subsidiary Canadian Nuclear Partners (CNP) plans to provide irradiation services to support BWXT’s new medical isotope manufacturing technology for molybdenum-99.2018-06-20T08:08:00-04:00df8fbf74-96fa-40d8-ae0f-65f6e0282891https://www.bwxt.com/bwxt-medical/news/2018/05/07/BWXT-Announces-Breakthrough-Medical-Isotope-Manufacturing-TechnologyBWX Technologies, Inc. announced today that it has developed an innovative and unique process to manufacture molybdenum-99 (Mo-99) that will enable a stable, North American supply of this critical diagnostic imaging radionuclide. 2018-05-07T07:12:00-04:00d4c2db49-a44b-4bc5-b567-1f2d44a14c6ehttps://www.bwxt.com/bwxt-medical/news/2018/04/17/BWXT-Announces-Strategic-Acquisition-of-Sotera-Health%E2%80%99s-Nordion-Medical-Isotope-Business-BWX Technologies, Inc. (NYSE:BWXT) (“BWXT” or the “Company”) announced today that it has signed a definitive agreement to acquire Sotera Health’s Nordion medical isotope business. 2018-04-17T07:33:00-04:00